fda glp-1 warning september 2025 news Prescription by Algorithm: The Ethical and Legal Questions Behind Advertising Beyond the Headlines: FDA Warning

As research into combination therapies progresses, determining the optimal dosing regimens, identifying potential drug interactions, and ensuring long-term safety will be crucial to unlocking the full potential of this approach and maximizing its impact on obesity treatment

There is an increasing focus on the potential contributory mechanistic role of the gut microbiota in the metabolic effects of glucoregulatory and weight loss promoting drugs, including glucagon-like peptide-1 (GLP-1) receptor agonists, which have become well-established therapies in type 2 diabetes and obesity 16,17

Also diarrhoea, peripheral vascular thrombosis, transitory exanthema, or urticaria

Polyunsaturated fatty acids and their metabolites in brain function and disease

We really dont know the long-term ramifications of these drugs